

Medical Policy: AZACITIDINE (VIDAZA®)

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.14	July 28, 2023	October 2016

Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Azacitidine is a pyrimidine nucleoside that interferes with DNA leading to cellular death. It is used to treat certain cancers.

Guideline

Subcutaneous or Intravenous azacitidine (Vidaza) may be considered medically necessary for any of the following:

1. Myelodysplastic Syndromes (MDS)
2. Acute myeloid leukemia (AML) — off-label use

Limitations/Exclusions

1. Azacitidine (Vidaza) is considered experimental or investigational for all other uses.
2. Contraindicated in patients with advanced malignant hepatic tumors
3. Patient must be 18 years of age or older.

Applicable Procedure Codes

Code	Description
J9025	Injection, azacitidine, 1 mg

Applicable NDCs

Code	Description
59572-0102-01	Vidaza single dose vial, 100 mg suspension reconstituted
68001-0313-56	Azacitidine single dose vial, 100 mg suspension reconstituted
68001-0504-54	Azacitidine single dose vial, 100 mg suspension reconstituted
71288-0115-30	Azacitidine single dose vial, 100 mg suspension reconstituted
71288-00153-95	Azacitidine single dose vial, 100 mg suspension reconstituted
43598-0305-62	Azacitidine single dose vial, 100 mg suspension reconstituted
00143-9606-01	Azacitidine single dose vial, 100 mg suspension reconstituted
72485-0201-01	Azacitidine single dose vial, 100 mg suspension reconstituted
16714-0927-01	Azacitidine single dose vial, 100 mg suspension reconstituted
69097-0805-40	Azacitidine single dose vial, 100 mg suspension reconstituted
16729-0306-10	Azacitidine single dose vial, 100 mg suspension reconstituted
43598-0678-11	Azacitidine single dose vial, 100 mg suspension reconstituted
51991-0797-98	Azacitidine single dose vial, 100 mg suspension reconstituted
63323-0771-39	Azacitidine single dose vial, 100 mg suspension reconstituted
43598-0465-62	Azacitidine single dose vial, 100 mg suspension reconstituted
64679-0096-01	Azacitidine single dose vial, 100 mg suspension reconstituted
64679-0096-02	Azacitidine single dose vial, 100 mg suspension reconstituted
67457-0254-30	Azacitidine single dose vial, 100 mg suspension reconstituted
00781-3253-94	Azacitidine single dose vial, 100 mg suspension reconstituted

ICD-10 Diagnoses

Code	Description
C92.00	Acute myeloblastic leukemia, not having achieved remission
C92.01	Acute myeloblastic leukemia, in remission
C92.02	Acute myeloblastic leukemia, in relapse
C92.40	Acute promyelocytic leukemia, not having achieved remission
C92.41	Acute promyelocytic leukemia, in remission
C92.42	Acute promyelocytic leukemia, in relapse
C92.50	Acute myelomonocytic leukemia, not having achieved remission
C92.51	Acute myelomonocytic leukemia, in remission
C92.52	Acute myelomonocytic leukemia, in relapse
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission
C92.61	Acute myeloid leukemia with 11q23-abnormality in remission
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse
C93.00	Acute monoblastic/monocytic leukemia, not achieve remission

C93.01	Acute monoblastic/monocytic leukemia, in remission
C93.02	Acute monoblastic/monocytic leukemia, in relapse
C93.90	Monocytic leukemia, unspecified, not having achieved remission
C94.00	Acute erythroid leukemia, not having achieved remission
C94.01	Acute erythroid leukemia, in remission
C94.02	Acute erythroid leukemia, in relapse
C94.20	Acute megakaryoblastic leukemia not having achieved remission
C94.21	Acute megakaryoblastic leukemia, in remission
C94.22	Acute megakaryoblastic leukemia, in relapse
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.1	Refractory anemia with ring sideroblasts
D46.20	Refractory anemia with excess of blasts, unspecified
D46.21	Refractory anemia with excess of blasts 1
D46.22	Refractory anemia with excess of blasts 2
D46.4	Refractory anemia, unspecified
D46.9	Myelodysplastic syndrome, unspecified
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.Z	Other myelodysplastic syndromes

Revision History

Company(ies)	DATE	REVISION
EmblemHealth & ConnectiCare	7/28/2023	<p>Annual Review:</p> <p>Removed the following for <u>Myelodysplastic Syndromes (MDS)</u> Initial Criteria:</p> <ul style="list-style-type: none"> a. “For high risk MDS in members who meet one of these criteria: <ul style="list-style-type: none"> i. Not a candidate for high-intensity therapy (e.g., allogenic hematopoietic stem cell transplant) ii. Candidate for high-intensity therapy who is awaiting improvement in status or a transplant iii. Member has no response or relapse after stem cell allogenic hematopoietic transplant b. For low-risk members who meet one of the following criteria: <ul style="list-style-type: none"> i. Use for initial treatment in members with significant increase in marrow blasts, thrombocytopenia, or neutropenia ii. Use for initial treatment in members with symptomatic anemia who have no deletion 5q abnormality, serum erythropoietin > 500 mU/mL and low likelihood of improvement with immunosuppressive therapy iii. Use for treatment in members who have symptomatic anemia with serum erythropoietin < 500 mU/mL, have failed erythropoietin therapy and failed immunosuppressive therapy

		<p>iv. Use for treatment in members with deletion 5q abnormality who have serum erythropoietin > 500 mU/mL, have failed lenalidomide and have low likelihood of response to immunosuppressive therapy”</p> <p>And Removed the following for Acute <u>myeloid leukemia (AML)</u> — off-label use: Initial Criteria</p> <p>c. “For members ≥ 60 years of age who meet one of the following criteria:</p> <p>i. Use for induction therapy as a single agent or in combination with either Venclexta (venetoclax) or Nexavar (sorafenib)</p> <p>ii. Use for post-remission/maintenance therapy as a single agent</p> <p>iii. Use for post-induction therapy as a single agent or in combination with either Venclexta (venetoclax) or Nexavar (sorafenib); OR</p> <p>d. For members with relapsed/refractory disease as a single agent or in combination with Nexavar (sorafenib)”</p>
EmblemHealth & ConnectiCare	3/30/2022	Transferred policy to new template
EmblemHealth & ConnectiCare	10/05/2020	<p>Removed: AML off-label use for:</p> <p>“Members > 60 years of age as a single agent for induction or post-remission therapy</p> <p>Either as a single agent or with nexavar (sorafenib) in members who cannot tolerate or have failed more intensive therapies”</p> <p>Clarified AML off-label use in accordance with NCCN guidelines</p>
EmblemHealth & ConnectiCare	04/08/2020	Added under Limitations/Exclusions: Contraindicated in patients with advanced malignant hepatic tumors and Patient must be 18 years of age or older per FDA label
EmblemHealth & ConnectiCare	10/24/2016	Clarified prerequisite serum erythropoietin levels.

References

1. Estey, Elihu H, et al. Treatment of intermediate, low, or very low risk myelodysplastic syndromes. UpToDate, Waltham, MA. August 2017. <http://www.uptodate.com/contents/treatment-of-intermediate-low-or-very-low-risk-myelodysplastic-syndromes>. Accessed September 30, 2019.
2. Azacitidine (Vidaza) [package insert]. Summit, NJ: Celgene Corporation; 2004, revised September 2019.
3. National Comprehensive Cancer Network (NCCN). Azacitidine. NCCN Drug & Biologics Compendium®. 2016.
4. Specialty matched clinical peer review.